NEW YORK (GenomeWeb News) – Catch by Gene (CBYG) today announced a reagent supply agreement with C&S.
The deal, which is initially for $300,000, covers CBYG's test kit products for the identification of sexually transmitted diseases, including the early-stage identification of human papillomavirus. CBYG will initially provide C&S with 60,000 reagents a year, and said in a statement that it anticipates that amount to increase each year "with increased demand requirements in addition to other international distributors."
The Korean company develops, manufactures, and markets in vitro nucleic acid assays. Its technology uses multi-probes based on microplate chemiluminescence or colorimetry for the direct detection of infectious pathogens, such as hepatitis B, HPV, and Chlamydia trachomatis, the company said.